logo
logo
Quest Diagnostics Incorporated

Quest Diagnostics Incorporated

NYSE•DGX
CEO: Mr. James E. Davis
セクター: Healthcare
業種: Medical - Diagnostics & Research
上場日: 1996-12-17
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
連絡先情報
500 Plaza Drive, Secaucus, NJ, 07094, United States
973-520-2700
www.questdiagnostics.com
時価総額
$22.96B
PER (TTM)
23.0
34
配当利回り
1.6%
52週高値
$207.00
52週安値
$157.20
52週レンジ
97%
順位24Top 10.8%
5.7
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 5.7 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$2.81B+0.00%
直近4四半期の推移

EPS

$2.21+0.00%
直近4四半期の推移

フリーCF

$0.00+0.00%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Nine Month Revenue Growth Total net revenues reached $8,229M, marking a strong 13.5% increase for the nine months ended September 30, 2025.
Operating Income Rises Operating income grew 18.7% to $1,170M for the nine months, showing improved operational efficiency compared to prior year.
Net Income Improvement Net income attributable to Quest Diagnostics increased 15.0% to $747M for the nine months period.
Strong Operating Cash Flow Net cash provided by operating activities totaled $1,421M for the nine months, significantly exceeding the prior period.

リスク要因

Restructuring Charge Incurred Pre-tax charges of $37M were recorded for the Invigorate restructuring program during the nine months ended September 30, 2025.
Asset Exit Impairment Recorded a $29M impairment charge on long-lived assets related to exiting a specific business during the nine months.
Cash Position Reduced Consolidated cash and equivalents decreased by $117M since year-end 2024, ending the quarter at $432M.
Contingent Liability Growth Contingent consideration obligation increased to $114M as of September 30, 2025, reflecting prior acquisition adjustments.

見通し

Spectra Acquisition Completed Acquired select clinical testing assets from Spectra Laboratories for $34M cash consideration in August 2025.
Corewell Health Venture Planned Signed agreement for a Michigan laboratory testing venture with Corewell Health, expecting facility operation in 2027.
Capital Expenditure Estimate Estimate approximately $500M in capital expenditures planned for 2025 to support diagnostic offerings growth.
Regulatory Impact Assessment Currently assessing impact of OBBBA legislation and enhanced PTC expiration on future revenue streams through 2028.

同業比較

売上高 (TTM)

Tenet Healthcare CorporationTHC
$20.86B
-0.6%
Genmab A/SGMAB
$14.04B
+21.0%
Labcorp Holdings Inc.LH
$13.77B
+8.3%

粗利益率 (最新四半期)

Genmab A/SGMAB
94.3%
-0.7pp
Incyte CorporationINCY
92.0%
+1.8pp
United Therapeutics CorporationUTHR
87.4%
-1.5pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
NTRA$29.28B-93.9-25.1%10.1%
MTD$28.61B32.8-487.2%58.0%
BIIB$27.73B21.47.3%23.6%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
1.9%
緩やかな成長
4四半期純利益CAGR
3.7%
収益性の緩やかな改善
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい

深度リサーチ

次回決算:2026年4月20日
|
EPS:-
|
売上高:-
財務レポート
財務データ
全年度
  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年10月21日|
    売上高: $2.82B+13.2%
    |
    EPS: $2.18+8.5%
    予想を下回る
  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年7月23日|
    売上高: $2.76B+15.2%
    |
    EPS: $2.51+22.4%
    予想通り
  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年4月23日|
    売上高: $2.65B+12.1%
    |
    EPS: $1.97+13.2%
    予想を下回る
  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月20日|
    売上高: $9.87B+6.7%
    |
    EPS: $7.80+2.8%
    予想を上回る
  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年10月23日|
    売上高: $2.49B+8.4%
    |
    EPS: $2.01+1.0%
    予想を下回る
  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年7月24日|
    売上高: $2.40B+2.5%
    |
    EPS: $2.05-1.9%
    予想を下回る
  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年4月24日|
    売上高: $2.37B+1.5%
    |
    EPS: $1.74-2.8%
    予想を下回る
  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月22日|
    売上高: $9.25B-6.4%
    |
    EPS: $7.59-6.5%
    予想を上回る